Key result
Percutaneous MCS fails to show convincing clinical benefit despite hemodynamic gains across randomized trials.
Why the study?
As older, comorbid patients with complex coronary disease undergo high-risk PCI, success increasingly depends on MCS devices to provide hemodynamic support and LV unloading.
This review highlights the role, patient selection, and optimal timing of mechanical circulatory support devices to potentially increase clinical benefit during high-risk PCI and AMI complicated by cardiogenic shock.
Answers are grounded in this paper and cite their sources.
MCS use in high-risk PCI or shock should await RCT confirmation of clinical benefit; leaves open optimal device selection and timing.
Given the tremendous progress in interventional cardiology over the last decade, a growing number of older patients, who have more comorbidities and more complex coronary artery disease, are being considered for technically challenging and high-risk percutaneous coronary interventions (PCI). The success of performing such complex PCI is increasingly dependent on the availability and improvement of mechanical circulatory support (MCS) devices, which aim to provide hemodynamic support and left ventricular (LV) unloading to enable safe and successful coronary revascularization. MCS as an adjunct to high-risk PCI may, therefore, be an important component for improvement in clinical outcomes. MCS devices in this setting can be used for two main clinical conditions: patients who present with cardiogenic shock complicating acute myocardial infarction (AMI) and those undergoing technically complex and high-risk PCI without having overt cardiogenic shock. The current article reviews the advancement in the use of various devices in both AMI complicated by cardiogenic shock and complex high-risk PCI, highlights the available hemodynamic and clinical data associated with the use of MCS devices, and presents suggestive management strategies focusing on appropriate patient selection and optimal timing and support to potentially increase the clinical benefit from utilizing these devices during PCI in this high-risk group of patients.
No takes yet. Share an insight, caveat, or question.
Asleh et al. (2019) conducted a review in Cardiogenic shock complicating acute myocardial infarction and high-risk percutaneous coronary interventions. Percutaneous Mechanical Circulatory Support Devices was evaluated. Despite accumulating evidence of hemodynamic improvement using various mechanical circulatory support devices, a convincing clinical benefit based on randomized controlled trials has not yet been demonstrated among this population.
Synapse has enriched 10 related papers. Consider them for comparative context: